Brainstrorm Cell Therpay

BrainStorm Cell Therapeutics, Inc.

OTC BB: BCLI

Executive Summary

October 2007

Contact information:

Chaim Levinson

Investor Relations Director

Clevinson@brainstorm-cell.com

Mobile: 972-545-633683

BrainStorm’s Value Proposition

BrainStorm is an early stage biotechnology company focused on developing innovative adult stem cell therapies for highly debilitating neurodegenerative disorders, such as Parkinson’s disease, Amyotrophic Lateral Sclerosis (also known as Lou Gehrig's disease), Multiple Sclerosis and spinal cord injury. Addressing the core pathology underlying neurodegenerative diseases rather than treating their symptoms, NurOwnв„Ñž treated patients are expected to enjoy a rapid recovery and much enhanced quality of life.

BrainStorm’s NurOwnв„Ñž therapy will provideвЂ"after full commercializationвЂ"compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By treating debilitating diseases, BrainStorm will enable healthcare institutions and society at large to realized massive savings in treatment and care costs.

This executive summary contains forward-looking statements that address a variety of subjects including, for example, the expected development and growth of markets in which BrainStorm Cell Therapeutics operates, expected future advances and expansion, expected revenue growth and opportunities, expected cash resources and equity and/or debt financings, the further execution of BrainStorm’s strategic business plan and growth of its businesses. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: BrainStorm’s success, including its ability to improve its cash position, and expand its operations and revenues, depends on its ability to execute on its business strategy and the continued demand for and market acceptance of its products and services; BrainStorm may not be able to expand its operations in accordance with its business strategy and BrainStorm’s cash balances may not be sufficient to allow BrainStorm to meet all of its business goals. For a detailed discussion of cautionary statements that may affect BrainStorm’s future results of operations and financial results, please refer to BrainStorm’s filings with the Securities and Exchange Commission, including its most recent quarterly report on Form 10-QSB. Forward-looking statements represent management's current expectations and are inherently uncertain. We do not undertake any obligation to update forward-looking statements made by us.

Executive Summary

Neurodegenerative diseases are devastating. We are all familiar with themвЂ"Parkinson’s disease (PD), Alzheimer’s disease (AD), Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS)вЂ"and most of us have been affected personally, through a family member or close friend. Neurodegenerative diseases are characterized by slow progression, and thus typically do not directly kill their victims; rather, they ravage their quality of life.

BrainStorm Cell Therapeutics inc (OTCBB:BCLI). is pioneering research and development in adult bone marrow-derived stem cell therapy aimed at treating these debilitating diseases. Guided by the desire to see the results of their efforts within their lifetime, BrainStorm’s scientific team and business managers have chosen to focus their first commercialization efforts on combating Parkinson’s, and ALS diseases. In Parkinson, the disease mechanism is well understood by the scientific community. The Company has aimed its treatment strategy at a clearly delineated site in the brain, therefore presenting an opportunity to shorten the time-to-market.

NurOwnв„Ñž

BrainStorm’s core technology, NurOwnв„Ñž, is based on the breakthrough scientific achievements of Professor Eldad Melamed, Head of Neurology, Rabin Medical Center, Tel-Aviv University, and a member of the Scientific Committee of the Michael J. Fox Foundation for Parkinson's Research, and Dr. Daniel Offen, Head of the Neuroscience Lab, Felsenstein Medical Research Center (FMRC) at Tel-Aviv University.

The NurOwnпÑ"" technology processes adult human mesenchymal stem cells, which are present in bone marrow and are capable of self-renewal as well as differentiation into many other tissues. The research team is among the first to have successfully achieved the in vitro differentiation of adult bone marrow cells (animal and human) into characteristic neuron-like cells capable of releasing dopamine and astrocyte-like cells capable of releasing several neurotrophic factors, including glial-derived neurotrophic factor (GDNF). Dopamine cell damage and death is the hallmark of Parkinson’s disease (PD). Astrocytes have been found to protect healthy dopamine-producing cells, as well as to repair degenerated cells, preventing the progression of Parkinson’s and other neurodegenerative diseases. BrainStorm’s NurOwnпÑ"" therapy for PD seeks to replace degenerated dopamine-producing nerve cells and strengthen them with supporting astrocytes that release a number of neurotrophic factors. The ability to induce differentiation into astrocytes-like cells makes NurOwnпÑ"" technology highly attractive for treating other diseases (such as ALS and MS) and conditions (such as stroke and spinal cord injury).

NurOwnпÑ"" technology is patent pending worldwide:

• The NurOwn TM technology for differentiation of dopamine-producing neuron-like cells is covered by application number PCT/IL03/00972 filed in November 2003. The patent was filed in the USA, Canada, Europe, Japan, Singapore, Australia, and Israel.

• The NurOwnв„Ñž technology for differentiating astrocyte-like cells is covered by PCT patent application number PCT/IL2006/000699, filed on June 18, 2006.

• The NurOwn TM technology for generating oligodendrocyte-like